CoChat

Progression of X‐linked adrenoleukodystrophy under interferon‐β therapy

Korenke, G. C., Christen, H.‐J., Kruse, B., Hunneman, D. H., Hanefeld, F. · 1997 · Journal of Inherited Metabolic Disease
Cited by 29

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

The cerebral phenotype of X‐linked adrenoleukodystrophy (ALD) is a rapidly progressive neurodegenerative disorder characterized by a cerebral inflammatory response and elevated very long‐chain fatty acids (VLCFA). Interferon‐β (INFB) is known to suppress the synthesis of tumour necrosis factor α and interferon‐γ, which have been reported to be elevated in the margin of the areas of demyelination in ALD brains. We report on treatment with interferon‐β in 8 patients with cerebral ALD, who additionally received glycerol trioleate/glycerol trierucate. INFB‐1a (Rebif, Serono, Switzerland) was given subcutaneously once a week, 3 million units for the first 3 months and 6 million units for the next 9 months. All patients showed an unimpeded progression of neurological symptoms during INFB therapy. Therapy was stopped within 6 months in 4 patients because of the fast neurological deterioration with loss of walking. In all patients the MRI demonstrated a progression of demyelination with a qualitatively unchanged gadolinium enhancement. Further studies are needed to elucidate the pathomechanism of demyelination in ALD in order to find an effective therapy for cerebral ALD patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1023/a:1005361607523

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 29

Metadata

Authors
Korenke, G. C., Christen, H. ‐., Kruse, B., Hunneman, D. H., & Hanefeld, F.
Venue
Journal of Inherited Metabolic Disease
Publisher
Wiley
Published
1997-03
Volume
20
Issue
1
Pages
59-66
ISSN
  • 0141-8955 (ISSN-L)
  • 1573-2665
OpenAlex
W137925544
Cited by
29
References
6
FWCI
0.85
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.